CESM to monitor and predict response to neo-adjuvant chemotherapy
Research type
Research Study
Full title
CESM to monitor and predict response to chemotherapy in patients already diagnosed with breast cancer
IRAS ID
228550
Contact name
Ruxandra Pietrosanu
Contact email
Sponsor organisation
Guy's and St Thomas Foundation Trust
Duration of Study in the UK
1 years, 6 months, 1 days
Research summary
Currently patients undergoing neo-adjuvant chemotherapy (prior to surgery) for breast cancer are monitored with MRI for treatment response. Relatively recently we have introduced the use of contrast enhanced mammography (CESM) to the department and there is emerging evidence that this modality may be an effective alternative means for treatment response monitoring. We propose that all women within the breast department diagnosed with a new breast cancer undergoing primary chemotherapy over a 6-12 month period will have both interval MRI and CESM allowing for a comparison of the two modalities. CESM is a fast procedure, suitable for patients with contraindications to MRI and is cost saving alternative to MRI and this research may allow for the introduction of its routine use in neoadjuvant chemotherapy monitoring.
REC name
Wales REC 6
REC reference
18/WA/0116
Date of REC Opinion
4 Apr 2018
REC opinion
Further Information Favourable Opinion